-
1 What is the purpose of these clinical research studies?
The purpose of BE OPTIMAL and BE COMPLETE is to see if the investigational study drug, which is called bimekizumab, is safe and effective for treating adults with active psoriatic arthritis.
-
2 How will I know if I am eligible to join?
If you would like to learn more about joining, please visit the “Can I join?” page. If you meet the key study criteria, you can contact a study clinic local to you. The staff at the study clinic will discuss the study details with you and will also ask you a number of medical questions to see if you are eligible to participate.
-
3 What should I consider before taking part in a clinical research study?
Before taking part in a clinical research study, you may want to discuss it with people close to you. For example, your doctor may offer medical advice, and your family and friends could offer their perspectives on your decision. You may also want to discuss your participation with a patient support group or with other patients who have previously taken part in clinical research.
-
4 Will I have to switch doctors?
No. Clinical research studies provide short-term care specific to the study for the length of each study. Clinical research studies do not provide long-term primary healthcare. At the end of the study, your care will return, in full, to your regular doctor.
-
5 How will I be compensated for my participation in these studies?
All investigational study drugs and study-related care are provided at no cost to you. Please refer to the Informed Consent Form for further details.
-
6 Where are the study clinics?
The study clinics are in North America, Europe, and Asia-Pacific.
-
7 What is the investigational study drug that is being tested?
Bimekizumab is an investigational study drug which has been developed for active psoriatic arthritis. Bimekizumab is given by subcutaneous injection (that is, an injection under the skin).
-
8 Who will have access to my name and the information collected during participation?
Your personally identifiable information (for example, name and address) will not be accessible to anyone who is not directly associated with this clinical research study, except with your permission or as required by law.
Any information that is gained from this clinical research study may be used for publishing results. However, this information will only be combined with other participant data and cannot be used to identify any given participant.
The sponsor of this clinical research study will not have access to any personally identifiable information submitted through this website without your permission.